Co-PI's Dr. Amy Johnson and Dr. John Byrd receive a RO1 grant for "Targeted Therapy for Lymphoid Malignancies."
The grant will fund research for "Targeted Therapy for Lymphoid Malignancies." The project has three aims; 1) perform a phase II clinical trial of ibrutinib in relapsed and refractory CLL. 2) To perform baseline and serial pharmacodynamic (PD) studies in the phase II ibrutinib study to determine if traditional genomic features, select BCR activation markers, and changes in miR marker expression are predictive for clinical response and 2-year PFS. As well as, 3) to perform studies derived from samples from patients participating in both this and other single agent ibrutinib trials to determine the biologic features of tumor cells not cleared from the blood by 12 months and pharmacologic strategies for novel combination strategies to eliminate these.